Davis Carolyn M, Fitzgerald Caitlin A, Jaffree Layla S, Ali Yasmin, Lee Timothy K, Lyons John D, Mittal Rohit, Liang Zhe, Martin Greg S, Suessmuth Yvonne, Ford Mandy L, Coopersmith Craig M
Department of Surgery and Emory Critical Care Center, Emory University School of Medicine, Atlanta, GA, USA.
Department of Medicine, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine and Emory Critical Care Center, Emory University School of Medicine, Atlanta, GA, USA.
Shock. 2025 May 12. doi: 10.1097/SHK.0000000000002627.
Epidermal growth factor (EGF) has healing effects on the intestinal mucosa and improves survival when administered systemically after the onset of pre-clinical sepsis. The intestine plays a key role in this improvement in mortality as transgenic mice that overexpress EGF only in the villus epithelium also have a survival benefit. However, EGF also has extra-intestinal effects mediated via the adaptive immune system. To determine whether systemic EGF alters the T cell response following sepsis, splenic flow cytometry was assayed in mice randomized to receive systemic EGF or vehicle. CD4+ T cell frequency was increased while CD8+ T cell frequency was decreased in septic mice following EGF, associated with a significant decrease in activated CD4+ T memory cells. Further, the exhaustion marker TIGIT was significantly upregulated following EGF on both conventional and regulatory CD4+ T cells. Based upon these findings and known crosstalk between the gut epithelium and the adaptive immune system, we asked whether the beneficial effects of systemic and intestine-specific EGF were dependent on the presence of an adaptive immune system. Rag1-/- mice lacking mature lymphocytes were randomized to receive either systemic EGF or vehicle following sepsis. In contrast to its beneficial effect in immunocompetent mice, EGF markedly worsened 7-day mortality in Rag1-/- mice. Similar to immunocompetent mice, EGF decreased gut epithelial apoptosis in Rag1-/- mice but lost its ability to improve either permeability or villus length. Further, when transgenic mice that overexpress intestine-specific EGF were crossed to Rag1-/- mice, intestine-specific EGF had no impact on survival following sepsis despite retaining its ability to decrease sepsis-induced gut epithelial apoptosis and permeability. Thus, although EGF is a potentially novel therapeutic in sepsis via improving gut integrity, EGF also changes T cell biology, and the survival advantage of EGF following sepsis is dependent, at least in part, on interactions between the gut and the adaptive immune system.
表皮生长因子(EGF)对肠黏膜具有愈合作用,并且在临床前脓毒症发作后全身给药时可提高生存率。肠道在这种死亡率改善中起关键作用,因为仅在绒毛上皮中过表达EGF的转基因小鼠也具有生存优势。然而,EGF还具有通过适应性免疫系统介导的肠外效应。为了确定全身给予EGF是否会改变脓毒症后的T细胞反应,对随机接受全身EGF或赋形剂的小鼠进行了脾脏流式细胞术检测。给予EGF后,脓毒症小鼠的CD4 + T细胞频率增加,而CD8 + T细胞频率降低,这与活化的CD4 + T记忆细胞显著减少有关。此外,在传统和调节性CD4 + T细胞上,给予EGF后耗竭标志物TIGIT显著上调。基于这些发现以及肠道上皮与适应性免疫系统之间已知的串扰,我们询问全身和肠道特异性EGF的有益作用是否依赖于适应性免疫系统的存在。缺乏成熟淋巴细胞的Rag1-/-小鼠在脓毒症后随机接受全身EGF或赋形剂。与它在免疫活性小鼠中的有益作用相反,EGF显著恶化了Rag1-/-小鼠的7天死亡率。与免疫活性小鼠相似,EGF降低了Rag1-/-小鼠的肠道上皮细胞凋亡,但失去了改善通透性或绒毛长度的能力。此外,当过表达肠道特异性EGF的转基因小鼠与Rag1-/-小鼠杂交时,肠道特异性EGF对脓毒症后的生存没有影响,尽管它保留了降低脓毒症诱导的肠道上皮细胞凋亡和通透性的能力。因此,尽管EGF通过改善肠道完整性在脓毒症中是一种潜在的新型治疗方法,但EGF也会改变T细胞生物学,并且脓毒症后EGF的生存优势至少部分取决于肠道与适应性免疫系统之间的相互作用。